Reported 21 days ago
The weight-loss drug market is becoming increasingly competitive as companies like Roche, Novo Nordisk, and Eli Lilly develop new GLP-1 pills designed to rival the existing injectable options. Recent trial data suggests that these oral medications could achieve significant weight loss, yet concerns about side effects and patient preferences linger. As the landscape evolves, experts argue the need for diverse treatment options, stressing that patient response varies, making competition essential in addressing various obesity-related health issues.
Source: YAHOO